Abstract
This retrospective study evaluates the interest of CEA measurement for early detection of breast cancer recurrences. Among 804patients with invasive breast cancer, we selected 97patients without recurrence (WR) for 5years or more, 32with a local recurrence (LR) and 131with at least one distant metastasis (DM). Elevated CEA and CA15-3levels (>3.1μg/L and >26kU/L respectively) were found in 6% and 22% of patients with RL respectively and in 49% and 69% of patients with DM. Both CEA and CA15-3retained a significant value in predicting DM by univariate and multivariate analysis. Higher sensitivity of CEA and CA15-3were found in tumors with positive hormonal receptor status. CEA and CA15-3levels at DM were raised respectively in 23and 65% of the triple negative group, 58and 75% of the luminal, 56and 78% of the luminal-HER2and 50and 30% of HER2-enriched group (P=0.0094and 0.0252respectively). The combination of CEA and CA15-3increased CA15-3sensitivity in especially luminal and HER2-enriched groups. In conclusion, elevated CA15-3and CEA levels at initial diagnosis of recurrence were found to be associated with hormonal receptor status and breast cancer subtypes. The combination of CEA and CA15-3appeared useful especially luminal and HER2-enriched groups.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
